Myriad Genetics Inc. on Tuesday said its board approved an additional $200 million for its share buyback program. As of the end of its fiscal third quarter, the personalized medicine company said it repurchased more than $1.1 billion in stock since it started its buyback program in 2010, according to a news release. Shares of Myriad are down 20% in the year so far, underperforming the S&P 500 Index, which is up 3%.
Copyright © 2016 MarketWatch, Inc.
Continue Reading Below